百草枯中毒患者血清CRP与IL-6水平及相关性

百草枯(PQ),又名克芜踪、对草快,是目前使用最广泛的有机杂环类接触性和高效非选择性除草剂,对人、畜有很强的毒性,导致较高的急性中毒病死率,尤其是中毒后引起的多器官衰竭(MOF),是诱发患者死亡的重要原因[1,2].有研究表明,大量的炎性因子导致的全身炎症反应综合征(SIRS)可能是导致MOF的一个重要原因[3,4].本研究检测不同时段PQ中毒患者血清中C反应蛋白(CRP)、白细胞介素-6(IL-6)浓度的变化,探讨PQ中毒后炎性因子在MOF发生、发展过程中的作用.     

系统性红斑狼疮患者外周血IL-6、sIL-6R、CRP水平及相关性探讨

2000年2月至2004年8月,我们检测了36例系统性红斑狼疮(SLE)患者血清白介素-6(IL-6)、可溶性白介素受体-6(sIL-6R)及C反应蛋白(CRP)水平,并同正常人及活动期类风湿关节炎(RA)患者比较,以探讨IL-6、sIL-6R与sLE病情的关系及与CRP的相关性。     

感染猪囊尾蚴的家猪组织中不同时间IL-6、IL-8、TNF-α和sIL-2R含量变化

目的研究实验家猪感染猪囊尾蚴不同时间组织中细胞因子IL-6、IL-8、TNF-α和sIL-2R含量变化,从细胞因子角度探讨家猪抗猪带绦虫免疫应答的机制。方法用猪带绦虫虫卵直接灌胃20d龄健康乳猪4头,并以健康乳猪4头作对照。于感染后第40、60、80和120 d取实验组猪肝脏、骨骼肌、心肌、舌肌及脑组织中囊尾蚴寄生处组织200 mg匀浆,用ELISA法测定匀浆上清液中细胞因子IL-6、IL-8、TNF-α和sIL-2R的含量。结果1.肝脏病变组织中4种细胞因子的含量在40d时均明显高于同期对照组(P<0.01);随感染时间延长,4种细胞因子的含量逐渐降低,至80d时与同期对照组差别缩小(P<0.05),120d时肝脏已无囊尾蚴寄生;对照组肝脏组织中4种细胞因子的含量在不同时间始终保持基本稳定。2.肌肉和脑部份病变组织中4种细胞因子的含量在40d时也明显高于同期对照组(P<0.01);随感染时间延长至80d时与同期对照组差别变小(P<0.05),120d时与同期对照组差别无显著性(P>0.05)。3.对照组家猪肝脏中4种细胞因子的含量绝对值高于肌肉和脑组织(P<0.01);实验组肝组织在40d时各种细胞因子的增量更明显高于肌肉和脑组织中的增量(P<0.01)。结论家猪感染猪带绦虫早期,IL-6、IL-8和TNF-α作为前炎性反应因子在家猪肝脏的高水平表达诱导肝脏发生严重的炎症反应,限制和杀灭肝内的早期囊尾蚴,而肌肉和脑组织中这些细胞因子表达稍低,炎症反应相对较轻,因而囊尾蚴易于在这些部位存活。这一点可以从感染后期肌肉、脑组织中的囊尾蚴数量远多于肝脏而得到证实。     

急性心肌梗塞患者外周血IL-2、sIL-2R水平及动态变化的研究

本文测定了30例急性心肌梗塞患者外周血白细胞介素2（IL-2）及其游离受体（sIL-2R）水平，并进行动态观察，实验结果表明，发病后48h内IL-2水平最低，而sIL-2R水平最高，与正常对照组比较有显著性差异（P＜0.001）；发病后72hIL-2水平开始升高，sIL-2R水平开始下降，至2～3周时两者水平逐渐趋于正常，与对照组比较无显著性差异（P＞0．05）。研究表明急性心肌梗塞与机体免疫应答密切相关。     

斯奇康注射液及迪银片对银屑病患者血清sIL-2R、IL-2、TNF-α的影响

2000年1月至2002年11月，我科对99例寻常性银屑病患者采用斯奇康注射液及迪银片治疗，并观察治疗前后血清sIL-2R、IL-2和TNF-α变化及意义。     

食管癌患者血清IL-6、sIL-6R水平的监测及其临床意义

目的研究白细胞介素-6(IL-6)、可溶性IL-6受体(sIL-6R)在食管癌患者血清中的水平变化,以及IL-6与sIL-6R水平在肿瘤临床分期之间的相关关系,并探讨食管癌患者手术前后细胞因子水平的变化。方法用酶联免疫吸附试验(ELISA)方法检测了70例食管癌早期(Ⅰ~Ⅱ)患者、48例食管癌晚期(Ⅲ~Ⅳ)患者和130例对照者血清IL-6、sIL-6R水平,同时对118例食管癌患者手术前后的两项细胞因子指标进行动态观察。结果食管癌早期患者组和食管癌晚期患者组血清IL-6、sIL-6R水平均显著高于正常对照组(P<0.01),晚期患者较早期升高(P<0.01);食管癌转移组手术后血清IL-6、sIL-6R水平比手术前高(P<0.01),无转移组手术后两者水平较手术前明显降低(P<0.01),食管癌患者血清IL-6及sIL-6R水平与肿瘤的恶性化程度有明显相关性。结论sIL-6R在食管癌发病过程中可能起着促进作用,并可以与IL-6起协同作用,两者的免疫失调状态可能与食管癌密切相关;IL-6、sIL-6R水平可作为食管癌病情监测的指标,同时对肿瘤的临床分期、疗效和预后的判断也有一定的帮助。     

恶性肿瘤患者胸腺移植术前后血清IAP、sIL-2R水平变化及其临床意义

1997年2月～2000年9月，我们采用重建血运、同种异体全胸腺移植术辅助治疗26例恶性肿瘤患者，并对移植前后患者血清IAP、sIL-2R进行了检测，现报告如下。     

各型乙型肝炎患者血清sIL-2R、IFN-γ和IL-l变化的研究

目的:探讨各型乙型肝炎患者血清sIL-2R、IFN-γ和IL-l变化及其临床意义。方法:收集急性肝炎、慢性肝炎、慢性重型肝炙和活动性肝硬变患者血清标本各16份,16例健康人血清标本作为正常对照组,采用酶联免疫吸附试验(ELISA)检测各型乙型肝炎患者血清中sIL-2R和IFN-γ水平,采用MTT法检测各型乙型肝炎患者血清中IL-1水平,并与正常对照组进行比较。结果:急性肝炎患者血清sIL-2R、IFN-γ和IL-1水平均明显升高(P<0.01);慢性肝炎患者血清sIL-2R水平升高(P<0.05),IFN-γ水平无明显变化,IL-1水平稍降低;慢性重型肝炎患者血清sIL-2R和IFN-γ水平升高(P<0.05 and P<0.01 respectiveIy).但IL-1水平降低;活动性肝硬变患者血清sIL-2R和IFN-γ水平明显升高(P<0.01),但IL-1水平无明显变化。结论:血清sIL-2R、IFN-γ和IL-1参与各型乙型肝炎的发病机制,调整血清中细胞因子含量可能有助于乙型肝炎的治疗。     

阿尔茨海默病患者与同龄正常人血脂、血清CRP、Hcy及sIL-6R等的比较

阿尔茨海默病(AD)是老年人的常见病。β淀粉样蛋白(Aβ)斑块的形成伴随中枢神经炎性损害是AD的主要病理特点。研究表明,血脂在Aβ形成代谢中发挥着重要作用[1],同时白细胞介素(IL-6)及其可溶性受体(sIL-6R)在中枢神经炎性损害过程中也起着关键性作用[2],而高浓度同型半胱氨酸(H     

联合应用sIL-5Rα及sIL-13Rα2对哮喘小鼠IgE、INF-γ水平的影响

目的探讨联合应用sIL-5Rα及sIL-13Rα2对哮喘小鼠IgE、INF-γ水平的影响。方法50只BALB／c小鼠随机分为正常组、哮喘组、sIL-5Rα治疗组、sIL-13Rα2治疗组及联合slL-5Rα、sIL-13Rα2治疗组（简称联合治疗组）。哮喘组及治疗组用鸡卵蛋白（OVA）和氢氧化铝致敏,用OVA激发,建立小鼠哮喘模型,正常组用生理盐水代替,其中sIL-5Rα治疗组、sIL-13Rα2治疗组及联合治疗组分别于激发前30min腹腔注射100μg sIL-5Rα、sIL-13Rα2及联合应用sIL-5Rα及sIL-13Rα2各100μg,正常组和哮喘组激发前30min腹腔注射相同体积生理盐水。比较各组支气管肺泡灌洗液（BALF）及血清IgE、INF-γ水平变化。结果与正常组比较,哮喘组BALF及血清中IgE含量明显升高,而INF-γ含量明显降低（P〈0．01）;联合治疗组可有效降低BALF及血清中IgE含量,同时可升高INF-γ的含量,与哮喘组比较有显著性差异（P〈0．01）;与单独治疗组相比,联合治疗组亦具有显著性差异（P〈0．01）。结论联合应用sIL-5Rα及sIL-13Rα2治疗哮喘小鼠,可明显降低BALF及血清中IgE含量,同时升高INF-γ含量,从而达到缓解和治疗哮喘的目的。     

Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling

Tocilizumab, humanized anti-IL-6R antibody is a novel anti-rheumatic drug. In the present study, we examined the influence of tocilizumab on the inhibitory activity of soluble gp130 (sgp130) against IL-6 signaling. BAF-h130 cells, human gp130 transfected mouse pro-B cell line, were cultured with the mixture with IL-6, sIL-6R and sgp130 for 72 h. BAF-h130 cells proliferated by the addition of both IL-6 and sIL-6R, but not IL-6 or sIL-6R alone. The proliferation induced by IL-6/sIL-6R complex was inhibited by sgp130 concentration-dependently. Tocilizumab inhibited IL-6/sIL-6R-induced cell proliferation. On the other hand, it did not affect the suppressive property of sgp130. To examine if tocilizumab can dissociate IL-6/sIL-6R/sgp130 complex, we established an ELISA system to detect IL-6/sIL-6R/sgp130 complex using anti-IL-6R coated ELISA plate. The results clearly indicated that ELISA system established was detectable IL-6/sIL-6R/sgp130 complex in a concentration dependent manner. Tocilizumab was added to IL-6/sIL-6R/sgp130 complex-fixed plate and then remaining IL-6/sIL-6R/sgp130 complexes on the plate were measured. The amount of IL-6/sIL-6R/sgp130 complexes on the plate was not changed by the addition of tocilizumab. In conclusion, tocilizumab exerts its inhibitory effect through the inhibition of IL-6R directly without affecting natural inhibitor sgp130.     

Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis

Our objective was to evaluate the levels of interleukin-6 (IL-6), soluble receptors of IL-2 (sIL-2R), IL-10, and IL-1 receptor antagonists (IL-1ra) in the serum of patients with psoriatic arthritis (PsA) and to assess the correlation between these levels and parameters of clinical activity of skin and joint disease. In total, 34 patients with PsA and ten healthy volunteers participated in the study. Assessment of joint disease included duration of morning stiffness, number of tender and swollen joints, right and left grip, the presence of inflammatory spinal back pain, and Schober test. Current severity of skin disease was graded according to the psoriasis area and severity index (PASI). Erythrocyte sedimentation rate (ESR) was determined as a marker of disease activity. Serum levels of IL-6, sIL-2R, IL-1ra, and IL-10 were measured by an enzyme immunoassay kit. Significantly higher serum levels of IL-6, sIL-2R, IL-1ra, and IL-10 were found in patients with PsA in comparison with healthy volunteers. A statistically significant correlation was found between levels of sIL-2R and PASI, whereas no association was found with clinical parameters of joint severity. Levels of IL-1ra correlated with the number of tender and swollen joints. No correlation was found between levels of IL-6, IL-10, and clinical parameters of skin and joint severity. In the group of patients with PsA, serum levels of sIL-2R clearly correlated with severity of skin disease, whereas levels of IL-1ra were associated with joint severity. Received: 18 June 1999 / Accepted: 1 October 1999     

老年肺癌患者IL-6、sIL-2R和T细胞亚群检测的临床意义

目的　探讨老年肺癌患者外周血 IL - 6、s IL- 2 R和 T细胞亚群活性的变化。方法　对老年肺癌患者化疗前、后及老年健康对照组应用流式细胞分析法测定 T细胞亚群 ,双抗体夹心法 (EL ISA)测定 IL - 6及 s IL- 2 R水平。结果　肺癌组 s IL - 2 R、IL- 6及 CD8高于对照组 (P<0 .0 5) ,而CD3 及 CD4水平低于对照组 ,化疗后 s IL - 2 R、IL- 6及 CD8水平明显下降 ,但仍高于对照组 ,CD3 及 CD4水平略升高 ,仍低于对照组。结论　 IL - 6、s IL-2 R及 T细胞亚群联合测定可以反映肺癌病人机体免疫功能状态 ,可作为判断疾病的预后和免疫调节治疗的客观指标。     

GP130 and c-kit signalling, initiated by the sIL-6R/IL-6 complex, is insufficient to expand the primitive adult bone marrow CD34+CD38- pre-CFU cell

 It has previously been shown that gp130 and c-kit signalling synergize for the ex vivo expansion of human cord blood (CB) CD34+ haematopoietic progenitor cells. We were interested in evaluating this synergy within an ontogenetically different haematopoietic tissue [i.e. adult bone marrow (BM)] and on a more primitive progenitor subset (i.e. CD34+CD38– cells), which are highly enriched for pre-colony forming unit (CFU) cells. These cells were plated out in a primary liquid culture supplemented with either interleukin (IL)-6+stem cell factor (SCF), IL-6+SCF+soluble IL-6 receptor (sIL-6R), IL-6+SCF+sIL-6R+IL-3+IL-1 or SCF+IL-3+IL-6+IL-1. Cell counting after liquid culture revealed an absolute expansion of 2.2-, 4.1-, 89.5- and 65.7-fold compared with initial cell input for the four-cytokine combinations, respectively. The secondary read-out assay revealed that this cell expansion in the liquid culture also resulted in CFU generation, with absolute cloning efficiencies of 0.002, 0.024, 12.13 and 7.73 (per cell initially present) for the respective cytokine combinations. These results indicate that gp130 and c-kit signalling alone (i.e. using IL-6+SCF+sIL-6R), in terms of both cell number and CFU generation, insufficiently stimulate primitive adult BM CD34+CD38– haematopoietic cells in order to reach a CFU generation comparable with that obtained after multifactor stimulation. Adding sIL-6R to the multifactor stimulation and compared with this multifactor stimulation, a 1.7-fold synergy in terms of cell expansion and a 3.0-fold synergy in terms of CFU generation are obtained. The sIL-6R/IL-6 complex thus has a narrower spectrum of action on primitive adult BM CD34+CD38– cells than on CB CD34+ cells. Received: 3 January 2000 / Accepted: 20 April 2000     

急性胰腺炎合并急性肺损伤与血清中IL-6变化的关联性研究

目的：探讨白细胞介素－6（IL－6）在急性胰腺炎合并急性肺损伤发生发展中的临床意义。方法入选患者96例,分为急性胰腺炎组62例及急性胰腺炎合并急性肺损伤组34例,以健康成人30名为对照组。采用放射免疫法测定血清中IL－6含量变化,进行统计学分析。结果急性胰腺炎组和急性胰腺炎合并急性肺损伤组IL－6值均高于对照组,急性胰腺炎合并急性肺损伤组高于急性胰腺炎组,差异均有统计学意义（ P＜0．05）。结论 IL－6作为炎症启动因子,参与急性胰腺炎合并肺损伤的病理生理过程。     

The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab

BackgroundIL-6 contributes significantly to the chronic inflammatory process of rheumatoid arthritis (RA). Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling originated by the IL-6/IL-6R complex, is an effective treatment. However, predictors of the response to tocilizumab are still required. We aimed to combine IL-6 and soluble IL-6R (sIL-6R) levels to identify groups of responses.MethodsHeparinized blood and clinical data from 63 RA patients were collected before treatment and after 3 and 6 months. Two-step clustering (SPSS v.18) was used to establish the relationship between IL-6 and sIL-6R. Then, we compared European League Against Rheumatism (EULAR) response criteria with remission achievement in the groups of patients.ResultsThree statistical significant clusters of RA patients (i.e., g1, g2, and g3) were defined by serum concentrations of IL-6 and sIL-6R at baseline. All groups of RA patients had higher IL-6 and sIL-6R levels than healthy donors. The levels of IL-6 expressed as median (IQR) in g1 patients were 124(90–183) pg/ml, in g2 12.3(4.4–24) pg/ml, and in g3 60.1(30–146) pg/ml (p < 0.001). The levels of sIL-6R expressed as mean ± sd in g1 patients were 250.5 ± 72 ng/ml, in g2 269.1 ± 125 ng/ml, and in g3 732.7 ± 243 ng/ml (p < 0.001). Disease activity score (DAS)28, C-reactive protein, and erythrocyte sedimentation rate were comparable in the three groups at baseline. Disease duration in g3 was the longest (median(IQR) years: g1 = 11(5–15), g2 = 12(8–20), and g3 23(16–26); p = 0.006), with years of disease evolution being correlated with sIL-6R levels (R = 0.417, p < 0.001). Simple and Clinical Disease Activity Index (SDAI and CDAI) decreased significantly in the three groups. However, EULAR response criteria and remission achievement at 6 m was different in the three groups (p = 0.03 and 0.04, respectively). In all. 17 out of the 18 patients in g1 had a good or moderate response to tocilizumab. Conversely, the percentage of patients with no response to tocilizumab was higher in g3 than in g1 and g2. We also observed different changing patterns of IL-6 and sIL-6R levels among the three groups.ConclusionsRA patients could be easily stratified prior to therapeutic intervention with two molecules related to the pathway blocked by tocilizumab. G1 patients, who had the best response to tocilizumab, had the highest level of IL-6 and the lowest level of sIL-6R.     

慢性肝病患者血清可溶性白细胞介素－6受体及其β链的检测及意义

目的观察慢性肝病患者血清可溶性白介素－６受体（Ｓｏｌｕｂｌｅ　ｉｎｔｅｒｌｅｕｋｉｎ－６ ｒｅｃｅｐｔｏｒ,ｓｉＬ－６Ｒ）和可溶性ＩＬ－６受体β链（ｓｇｐ１３０）的变化。方法应用酶联免疫吸咐法检测慢性肝炎患者４０例、肝炎后肝硬化患者１５例和３５例健康对照者血清中ｓＩＬ－６Ｒ和ｓｇｐ１３０水平。结果慢性肝炎患者血清ｓＩＬ－６Ｒ和ｓｇｐ１３０含量（μｇ／Ｌ）分别为２２４．２７和４８９．３５均显著高于健康对照组（ｕｇ／Ｌ）分别为１７４．８１和２７３．６４,其中肝炎后肝硬化组患者上述二参数高于慢性肝炎各组;慢性肝炎组中的上述二参数显示为重度＞中度＞轻度,各组间差异有显著意义;慢性肝病组血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平之间呈正相关（ｒ＝ ０．４８１, Ｐ＜ ００５）, ｓＩＬ－６Ｒ、 ｓｇｐ１３０水平与血清总胆红素水平间亦呈正相关（ｒ分别为０．４１７和０４２８, Ｐ值均＜ ０．０１）,与ＡＬＴ之间无明显相关性（ｒ分别为０．１７３和０１８２, Ｐ值均＞０．０５）。结论血清ｓＩＬ－６Ｒ和ｓｇｐ １３０与慢性肝病的病情演变有关,对其预后有一定指导意义。     

IL-2、IL-6及其受体与多发性骨髓瘤的研究

采用固相放射免疫分析法（ＲＩＡ）和双抗体夹心酶联免疫法（ＥＬＩＳＡ）,对多发性骨髓瘤（ＭＭ）患者进行血清白细胞介素２（ＩＬ－２）（ｓＩＬ－２Ｒ）,白细胞介素６（ＩＬ－６）,白细胞介素８受体（ｓＩＬ－６Ｒ）检测,并进行长期随访。结果ＭＭ患者血清ＩＬ０２、ｓＩＬ－２Ｒ和ＩＬ－６、ｓＨ－６Ｒ水平明显升高,ＩＬ－２与２微球蛋白＊β２－ＭＧ）呈负相关,ＩＬ－６,ｗＩＬ－８Ｒ与β－ＭＧ呈正相关,初诊时血清ｓＩ     

大承气冲剂对腹内感染致肺损伤患者BLAF中IL-6、IL-10浓度的影响

目的观察大承气冲剂对腹内感染（IAI）致急性肺损伤（ALI）患者局部免疫炎性因子IL-6、IL-10浓度的影响。方法将40例IAI合并ALI的患者随机分为对照组20例和中药组20例;对照组给予西医常规治疗＋安慰剂,中药组给予西医常规治疗＋大承气冲剂,疗程为5 d。记录患者排气、排便时间,并于治疗第1、3、5天分别测氧合指数（OI）及BLAF中IL-6、IL-10浓度。结果中药组排气、排便时间明显短于对照组（P均〈0.05）;中药组OI值较对照组明显升高（P〈0.05）;中药组BLAF中IL-6、IL-10浓度较对照组明显降低（P均〈0.05）。结论大承气冲剂可减轻IAI合并ALI患者局部炎症反应,促进免疫系统及肺肠功能的恢复。